MX2021000955A - Terapia de incremento mitocondrial para enfermedades mitocondriales primarias. - Google Patents

Terapia de incremento mitocondrial para enfermedades mitocondriales primarias.

Info

Publication number
MX2021000955A
MX2021000955A MX2021000955A MX2021000955A MX2021000955A MX 2021000955 A MX2021000955 A MX 2021000955A MX 2021000955 A MX2021000955 A MX 2021000955A MX 2021000955 A MX2021000955 A MX 2021000955A MX 2021000955 A MX2021000955 A MX 2021000955A
Authority
MX
Mexico
Prior art keywords
mitochondrial
primary
diseases
augmentation therapy
mitochondria
Prior art date
Application number
MX2021000955A
Other languages
English (en)
Spanish (es)
Inventor
Ohana Natalie Yivgi
Uriel Halavee
Shmuel Bukshpan
Noa Sher
Moriya Blumkin
Original Assignee
Minovia Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minovia Therapeutics Ltd filed Critical Minovia Therapeutics Ltd
Publication of MX2021000955A publication Critical patent/MX2021000955A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2021000955A 2018-07-22 2019-07-22 Terapia de incremento mitocondrial para enfermedades mitocondriales primarias. MX2021000955A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862701783P 2018-07-22 2018-07-22
US201862753947P 2018-11-01 2018-11-01
PCT/IL2019/050823 WO2020021536A1 (en) 2018-07-22 2019-07-22 Mitochondrial augmentation therapy for primary mitochondrial diseases

Publications (1)

Publication Number Publication Date
MX2021000955A true MX2021000955A (es) 2021-05-27

Family

ID=69181378

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000955A MX2021000955A (es) 2018-07-22 2019-07-22 Terapia de incremento mitocondrial para enfermedades mitocondriales primarias.

Country Status (11)

Country Link
US (1) US12502408B2 (https=)
EP (1) EP3823647A4 (https=)
JP (2) JP7522095B2 (https=)
KR (1) KR20210035212A (https=)
CN (1) CN112566645A (https=)
AU (1) AU2019311859B2 (https=)
BR (1) BR112021001190A2 (https=)
CA (1) CA3106186A1 (https=)
IL (1) IL280163B2 (https=)
MX (1) MX2021000955A (https=)
WO (1) WO2020021536A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2741757B1 (en) 2011-09-11 2018-05-16 Minovia Therapeutics Ltd. Compositions of functional mitochondria and uses thereof
US12551504B2 (en) 2018-07-22 2026-02-17 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of pancreatic diseases
US12329781B2 (en) 2018-07-22 2025-06-17 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of renal diseases
JP2021531288A (ja) 2018-07-22 2021-11-18 ミノヴィア セラピューティクス リミテッド 眼疾患のミトコンドリア増強療法
WO2020021536A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy for primary mitochondrial diseases
JP7524157B2 (ja) 2018-07-22 2024-07-29 ミノヴィア セラピューティクス リミテッド 脳疾患のミトコンドリア増強療法
JP7458368B2 (ja) 2018-07-22 2024-03-29 ミノヴィア セラピューティクス リミテッド 筋疾患のミトコンドリア増強療法
CA3172402A1 (en) 2020-03-31 2021-10-07 Minovia Therapeutics Ltd. Mitochondria-enriched genetically engineered cells and uses thereof
WO2021199032A1 (en) * 2020-03-31 2021-10-07 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy
WO2021224920A1 (en) * 2020-05-05 2021-11-11 Pluristem Ltd. Methods and compositions for enrichment of target cells
CN114699430A (zh) * 2022-04-12 2022-07-05 重庆理工大学 线粒体及其在胰腺炎中的应用和应用方法
US20260069634A1 (en) * 2022-04-27 2026-03-12 Paean Biotechnology Inc. Pharmaceutical composition, for preventing or treating hearing loss or tinnitus, comprising mitochondria as active ingredient
KR20250065545A (ko) * 2023-11-03 2025-05-13 서울대학교병원 미토콘드리아를 유효성분으로 포함하는 유전성 난청의 예방 또는 치료용 약학 조성물

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1150433A (zh) 1994-03-30 1997-05-21 米托科公司 线粒体缺陷相关疾病的诊断，治疗以及细胞和动物模型
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
JP2002538167A (ja) 1999-03-03 2002-11-12 バイオジェン インコーポレイテッド 脂質の代謝および貯蔵を調節する方法
GB2350565A (en) 1999-05-28 2000-12-06 Johnson & Johnson Medical Ltd Biological wound dressings comprising mitochondria
DE19937348A1 (de) 1999-08-11 2001-02-22 Aventis Cropscience Gmbh Nukleinsäuremoleküle aus Pflanzen codierend Enzyme, die an der Stärkesynthese beteiligt sind
US6773881B2 (en) 2000-03-31 2004-08-10 The General Hospital Corporation Methods of modulating hair growth
US7238727B2 (en) 2000-10-13 2007-07-03 Chugai Seiyaku Kabushiki Kaisha Compositions for improving lipid metabolism
US20030040475A1 (en) 2001-01-16 2003-02-27 Yasuhiro Toba Agents for improving lipid metabolism and reducing high blood pressure
US7339090B2 (en) 2001-02-13 2008-03-04 Avigenics, Inc. Microinjection devices and methods of use
JP4603192B2 (ja) 2001-05-10 2010-12-22 株式会社カネカ 毛髪頭皮用組成物
WO2003012050A2 (en) 2001-07-31 2003-02-13 Northeastern University Mitochondrial genome replenishment
AU2002324645C1 (en) 2001-08-08 2008-11-06 Levesque Biosciences, Inc. Compositions and methods for isolation, propagation, and differentiation of human stem cells and uses thereof
US7138134B2 (en) 2001-12-18 2006-11-21 Arizona Health Consulting Group, Llc Preparation and administration of jojoba product for reducing weight, fat and blood lipid levels
US20050153381A1 (en) 2002-02-14 2005-07-14 Marusich Michael F. Immunocapture of mitochondrial protein complexes
AU2004238375A1 (en) 2003-05-13 2004-11-25 The Regents Of The University Of Colorado Diagnostic and therapeutic treatments related to mitochondrial disorders
CA2526493A1 (en) 2003-05-22 2004-12-02 Theraptosis S.A. Means for preventing and treating cellular death and their biological applications
US7407800B1 (en) 2003-09-19 2008-08-05 Pierce Biotechnology, Inc. Method for the isolation of intact mitochondria from cells
EP1709084A4 (en) 2003-12-23 2008-05-28 Nono Inc POLYPEPTIDES FOR MODULATING BINDING OF TRP-CHANNEL PROTEINS AND TRP-ASSOCIATED PROTEINS
US20060024277A1 (en) 2004-07-27 2006-02-02 Sivak Hannah N Method of skin care and/or treatment using extracts enriched in mitochondria
JP2006131600A (ja) 2004-11-09 2006-05-25 R & D Cell-Science Optional Medico:Kk 発毛促進のためのヒト細胞組成物
EP2471530B1 (en) 2005-06-01 2017-01-11 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US20100047270A1 (en) 2005-06-10 2010-02-25 Albertsson Per-Aake Use of plant cell membrane for the treatment of obesity
AU2012201710B2 (en) 2006-05-11 2014-01-16 Regenics As Administration of cells and cellular extracts for rejuvenation
AT502353B1 (de) 2006-06-29 2007-07-15 Avl List Gmbh Verfahren und vorrichtung zur konditionierung eines o2-hältigen gases
EP2150117A4 (en) 2007-05-02 2011-10-05 Mclean Hospital Corp METHODS AND COMPOSITIONS FOR MITOCHONDRIA REPLACEMENT THERAPY
WO2008152640A2 (en) 2007-06-13 2008-12-18 Pluristem Ltd. Three dimensional biocompatible scaffolds for ex-vivo expansion and transplantation of stem cells
EP3029061B1 (en) 2008-06-18 2017-09-13 The Texas A&M University System Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
WO2011059547A2 (en) 2009-10-30 2011-05-19 Xenotech, Llc Cryopreservation of cells and subcellular fractions
US8846028B2 (en) 2010-10-28 2014-09-30 The Invention Science Fund I, Llc Mitochondrial enhancement of cells
JP6030067B2 (ja) 2010-12-03 2016-11-24 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的クリーム組成物および使用法
JP6054301B2 (ja) 2010-12-23 2017-01-11 アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ ミトコンドリア機能向上と、神経変性疾患および認知障害治療とのための組成物および方法
CA2847292A1 (en) 2011-06-29 2013-01-03 The General Hospital Corporation Compositions and methods for enhancing bioenergetic status in female germ cells
US20130022666A1 (en) 2011-07-20 2013-01-24 Anna Brzezinska Methods and compositions for transfer of mitochondria into mammalian cells
CN102266350A (zh) 2011-07-20 2011-12-07 黄必录 逆转干细胞衰老的方案
CN102293178A (zh) 2011-08-28 2011-12-28 黄必录 使个体去衰老的方法
EP2741757B1 (en) 2011-09-11 2018-05-16 Minovia Therapeutics Ltd. Compositions of functional mitochondria and uses thereof
EP3785767A1 (en) 2011-12-02 2021-03-03 Fate Therapeutics, Inc. Enhanced stem cell composition
US8648034B2 (en) 2011-12-09 2014-02-11 Changhua Christian Hospital Method and applications of peptide-mediated mitochondrial delivery system
WO2013149064A1 (en) 2012-03-30 2013-10-03 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Uridine diphosphate compounds as mobilizers of hematopoietic progenitor cells
US10702556B2 (en) 2012-05-16 2020-07-07 Minovia Therpautices Ltd. Compositions and methods for inducing angiogenesis
EP3459522B1 (en) 2012-12-10 2021-02-17 Regenics AS Use of egg cellular extracts for wound treatment
WO2014130518A1 (en) 2013-02-19 2014-08-28 Children's Medical Center Corporation Abcb5(+) stem cells for treating ocular disease
DE102013225588A1 (de) 2013-12-11 2014-04-17 Henkel Ag & Co. Kgaa Verwendung und Mittel zur Verbesserung der Haarstruktur
JP2017505819A (ja) 2014-02-04 2017-02-23 カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ Ｂ細胞悪性腫瘍及び他のがんの治療に有用な自己ｔ細胞を産生する方法、並びにその組成物
EP2918458B1 (en) 2014-03-11 2016-12-07 Autoliv Development AB A vehicle braking arrangement
WO2015142855A1 (en) 2014-03-17 2015-09-24 University Of Virginia Patent Foundation Compositions and methods for treating retinopathy
CN103976935A (zh) 2014-05-28 2014-08-13 广州市白云区天芳化妆品厂 一种抗衰原液及其制备方法
AU2015289644A1 (en) 2014-07-15 2017-02-02 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
WO2016008937A1 (en) * 2014-07-16 2016-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the intercellular transfer of isolated mitochondria in recipient cells
CN106795490B (zh) 2014-09-11 2021-01-19 台湾粒线体应用技术股份有限公司 用线粒体特化细胞治疗神经退行性疾病的医药组合物
JP6441472B2 (ja) 2014-09-30 2018-12-19 台灣粒線體應用技術股▲扮▼有限公司Ｔａｉｗａｎ Ｍｉｔｏｃｈｏｎｄｒｉｏｎ Ａｐｐｌｉｅｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．，Ｌｔｄ． 活性成分として外因性ミトコンドリアを含む組成物、ならびにその使用およびそのための細胞修復法
US20170327791A1 (en) 2014-11-14 2017-11-16 Jcr Pharmaceuticals Co., Ltd Muscular dystrophy therapeutic agent containing pluripotent stem cells derived from dental pulp
GB201500427D0 (en) 2015-01-12 2015-02-25 Isis Innovation Method
EP3244735A4 (en) 2015-01-14 2018-07-04 Calix Ltd Improved pathogen inhibitor
WO2016115632A1 (en) * 2015-01-21 2016-07-28 Exerkine Corporation Method for treating mitochondrial disease
WO2016133995A1 (en) 2015-02-17 2016-08-25 Arizona Board Of Regents On Behalf Of Arizona State University Phenothiazine analogues as mitochondrial therapeutic agents
IL299482B2 (en) * 2015-02-26 2025-02-01 Minovia Therapeutics Ltd Mammalian cells are enriched with active mitochondria
US10537594B2 (en) 2015-02-27 2020-01-21 University Of Connecticut Targeted transplantation of mitochondria to hepatocytes
CA2987064A1 (en) * 2015-05-28 2016-12-01 Celularity Inc. Placental-derived stem cells and uses thereof to restore the regenerative engine, correct proteomic defects and extend lifespan of aging subjects
US11903974B2 (en) 2015-11-30 2024-02-20 Flagship Pioneering Innovations V, Inc. Methods and compositions relating to chondrisomes from cultured cells
JP2017105729A (ja) 2015-12-10 2017-06-15 国立大学法人東北大学 ミトコンドリア病の治療剤
SI4272834T1 (sl) * 2016-01-15 2026-03-31 Beth Israel Deaconess Medical Center, Inc. Terapevtska uporaba mitohondrijev in kombiniranih mitohondrijskih sredstev
MX2019005127A (es) 2016-11-03 2019-09-26 Exostem Biotec Ltd Poblaciones y productos de células madre mesenquimales y sus usos.
WO2018088874A1 (ko) 2016-11-14 2018-05-17 주식회사 파이안바이오테크놀로지 외래 미토콘드리아를 세포로 전달하는 방법
EP3549589A4 (en) 2016-11-30 2020-07-15 Paean Biotechnology Inc. PHARMACEUTICAL COMPOSITION CONTAINING MITOCHONDRIA
US20200023005A1 (en) 2017-03-26 2020-01-23 Minovia Therapeutics Ltd. Mitochondrial compositions and methods for treatment of skin and hair
JP7524157B2 (ja) 2018-07-22 2024-07-29 ミノヴィア セラピューティクス リミテッド 脳疾患のミトコンドリア増強療法
JP2021531288A (ja) 2018-07-22 2021-11-18 ミノヴィア セラピューティクス リミテッド 眼疾患のミトコンドリア増強療法
JP2021532095A (ja) 2018-07-22 2021-11-25 ミノヴィア セラピューティクス リミテッド 肝臓疾患のミトコンドリア増強療法
WO2020021536A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy for primary mitochondrial diseases
US12551504B2 (en) 2018-07-22 2026-02-17 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of pancreatic diseases
JP7458368B2 (ja) 2018-07-22 2024-03-29 ミノヴィア セラピューティクス リミテッド 筋疾患のミトコンドリア増強療法
CN112601532A (zh) 2018-07-22 2021-04-02 米诺维亚疗法有限公司 使用富集有功能性线粒体的干细胞的线粒体增强疗法
EP3837359A4 (en) 2018-08-14 2022-05-11 Imel Biotherapeutics, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES OR DISORDERS AND HETEROPLASMIA
WO2020223576A1 (en) 2019-04-30 2020-11-05 Chondrial Therapeutics, Inc. Frataxin-sensitive markers for determining effectiveness of frataxin replacement therapy
WO2021199032A1 (en) 2020-03-31 2021-10-07 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy
CA3172402A1 (en) 2020-03-31 2021-10-07 Minovia Therapeutics Ltd. Mitochondria-enriched genetically engineered cells and uses thereof

Also Published As

Publication number Publication date
CN112566645A (zh) 2021-03-26
JP7522095B2 (ja) 2024-07-24
EP3823647A1 (en) 2021-05-26
IL280163B1 (en) 2025-09-01
CA3106186A1 (en) 2020-01-30
IL280163B2 (en) 2026-01-01
EP3823647A4 (en) 2022-06-01
KR20210035212A (ko) 2021-03-31
IL280163A (en) 2021-03-01
WO2020021536A9 (en) 2020-03-05
US12502408B2 (en) 2025-12-23
JP2021531284A (ja) 2021-11-18
JP2024138460A (ja) 2024-10-08
WO2020021536A1 (en) 2020-01-30
AU2019311859B2 (en) 2025-12-18
AU2019311859A1 (en) 2021-02-04
BR112021001190A2 (pt) 2021-04-27
US20210260137A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
MX2021000955A (es) Terapia de incremento mitocondrial para enfermedades mitocondriales primarias.
CY1125423T1 (el) Μεθοδος in vitro διαφοροποιησης των μεσεγκεφαλικων ντοπαμινεργικων(mda)νευρωνων
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
WO2019094642A8 (en) T cell manufacturing compositions and methods
EP4272834A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2023000049A (es) Metodos de acondicionamiento de pacientes para tratamiento con linfocitos t.
MY199581A (en) Plasminogen replacement therapy for plasminogen-deficiency
PH12020551427A1 (en) Epinephrine spray formulations
CL2018001677A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
EP4234568A3 (en) Solid forms of berberine ursodeoxycholate and compositions and methods thereof
MX2021000954A (es) Terapia de aumento mitocondrial con celulas madre enriquecidas con mitocondrias funcionales.
MX2020011016A (es) Composiciones para el tratamiento de condiciones de la piel.
PH12023552830A1 (en) Compositions and methods for inhibiting ketohexokinase
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
MX2021014905A (es) Células seguras e invisibles para el sistema inmunitario.
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
JOP20220259A1 (ar) تركيبات تشتمل على جسيمات نانونية، طريقة تصنيعها واستخدامها
MX2022000712A (es) Moduladores de nlrp3.
WO2018146679A3 (en) Photoreceptor cells for the treatment of retinal diseases
MX379201B (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
MX379359B (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
MX2022010868A (es) Cepas bacterianas, las composiciones de las mismas y uso de las mismas en un procedimiento para el tratamiento de la deficiencia de vitamina d, y trastornos asociados a la misma.
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.